05/11/2022
Grace Halupnik, MD; Nicholas Fedele, MD; Katie Comp, MD; Emma-Marie Taleb, MD; Andrew N. Shammas, BS , OMS, MD; Susan Jones-Miller, MD, MS; Venkat Shankarraman, MD, PhD; Nicolas W. Shammas, MD, MS, FACC, FSCAI, FACP, FSVM; Gail A. Shammas, BSN, BS , RN, BSc
The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the investigational device exemption study. At present, real-world data are not available. The...
The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the investigational device exemption study. At present, real-world data are not available. The...
The Auryon 355-nm laser...